- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Total revenues increase 4% over prior year quarter; Product & license revenues increase 31% over prior year quarter; Quarterly net loss attributable to common stockholders improves 70% to $0.7 million
Luna Innovations Incorporated /quotes/comstock/15*!luna/quotes/nls/luna (LUNA 2.12, -0.03, -1.40%) , a company focusing on sensing, instrumentation and nanotechnology, today announced its financial results for the second quarter and six months ended June 30, 2010.
As compared to the same quarter last year, total revenue increased by 4%, from $8.7 million in the second quarter of 2009 to $9.0 million in the second quarter of 2010, driven by a 31% revenue increase in the company's product and license segment, from $2.2 million in the second quarter of 2009 to $2.9 million in the second quarter of 2010. Operating expenses improved by $1.8 million, or 32%, due to the non-recurring costs incurred for litigation and reorganization activities in 2009, in addition to on-going expense savings initiatives. The company reported a net loss attributable to common stockholders of $0.7 million, or $0.05 per common share, for the second quarter of 2010, as compared to a net loss of $2.4 million, or $0.21 per common share for the second quarter of 2009. Adjusted EBITDA, which is earnings before interest, taxes, depreciation and amortization, excluding non-cash stock-based compensation expense, non-cash charges for impairment of intangible assets and charges related to the company's litigation with Hansen Medical, Inc. and its Chapter 11 reorganization, improved to $0.8 million for the second quarter of 2010, as compared to $0.5 million for the second quarter of 2009.
Dale Messick, Interim President and Chief Operating Officer, provided this overview of Luna's results: "Continued growth in our fiber optic test & measurement products has resulted in our return to year over year revenue growth overall. Along with this growth, we continue to be very pleased with the progress we are making in our bottom line results, adjusted EBITDA and cash flows now that the Hansen litigation and reorganization are behind us. Our adjusted EBITDA excluding litigation and reorganization-related items improved 80% compared to the second quarter of last year. Our net cash used in operating activities of $1.7 million for the first half of the year includes the impact of payment of approximately $1.9 million in pre-petition liabilities from the 2009 reorganization and related legal fees, absent which cash from operating activities would have been slightly positive for the first half of the year."
Second Quarter Financial Highlights
-- Total revenues increased by 4%, from $8.7 million for the second quarter of 2009 to $9.0 million for the second quarter of 2010.
-- Product and license revenues increased by 31% to approximately $2.9 million for the second quarter of 2010 from $2.2 million for the second quarter of 2009. Technology development revenues decreased by 6% to $6.1 million for the second quarter of 2010 from $6.5 million for the second quarter of 2009.
-- Gross profit for the second quarter of 2010 of $3.3 million was consistent with the gross profit realized in the second quarter of 2009.
-- Selling, general and administrative expenses decreased by 32% to $3.4 million, or 37% of total revenues for the second quarter of 2010, from $4.9 million, or 57% of total revenues, for the second quarter of 2009, driven by a reduction in litigation-related expenses.
-- Total operating expenses decreased to $3.8 million, or 42% of total revenues for the second quarter of 2010, from $5.6 million, or 65% of total revenues, for the second quarter of 2009.
-- Adjusted EBITDA excluding litigation and reorganization-related items increased to $0.8 million in the second quarter of 2010 from $0.5 million in the second quarter of 2009.
-- Net loss attributable to common stockholders improved to $0.7 million for the second quarter of 2010, compared to a net loss attributable to stockholders of $2.4 million for the second quarter of 2009.
-- Cash and cash equivalents totaled $6.3 million at June 30, 2010, as compared to $12.1 million at June 30, 2009 and $5.2 million at December 31, 2009. At June 30, 2010, $2.5 million continued to be outstanding under the company's revolving line of credit.
-- Sales of fiber optic test & measurement, sensing and instrumentation products increased 42% from $1.4 million in the second quarter of 2009 to $2.0 million in 2010.
-- Launched the portable Optical Backscatter Reflectometer(TM)(OBR) 4200 in the second quarter with potential applications in areas including telecommunications, medical imaging, aircraft and shipboard network verification.
Outlook for 2010
Based on information as of August 10, 2010, the company is lowering its guidance for the year due to a decline in the rate and timing of new contract awards in our Technology Development business segment. The company expects a net loss for the year in the range of $3.0 million to $4.0 million compared to its previous guidance of $2.8 million to $3.5 million. The company expects a revenue range of $33 million to $35.5 million; lowering its Technology Development revenue to be in the range of $23.0 to $24.0 million for the year and increasing its expectations on the product and license revenue of $10.0 million to $11.5 million for the full year. For the third quarter of 2010, the company expects revenue of approximately $8.5 million to $9.5 million and a net loss of approximately $0.5 million to $1.0 million.
In evaluating the operating performance of its business, Luna's management excludes certain charges and credits that are required by generally accepted accounting principles ("GAAP"). These non-GAAP results provide useful information to both management and investors by excluding items that the company believes may not be indicative of its operating performance, because either they are non-cash items or they are unusual items that the company does not expect to recur in the ordinary course of its business or are unrelated to the ongoing operation of the business in the ordinary course. These non-GAAP measures should be considered in addition to results and guidance prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. The non-GAAP measures included in this press release have been reconciled to the nearest GAAP measure in the table following the financial statements attached to this press release.
Conference Call Information
As previously announced, Luna Innovations will conduct an investor conference call at 5:00 p.m. (EDT) today to discuss its financial results and business developments for the second quarter of 2010. The call can be accessed by dialing 866.711.8198 domestically or 617.597.5327 internationally prior to the start of the call. The access code is 36809820. Investors are advised to dial in at least five minutes prior to the call to register. The conference call will also be webcast live over the Internet. The webcast can be accessed by logging on to the "Investor Relations" section of the Luna Innovations website, www.lunainnovations.com, prior to the event. The webcast will be archived under the "Webcasts and Presentations" section of the Luna Innovations website for at least 30 days following the conference call.
Forward Looking Statements:
The statements in this release that are not historical facts constitute "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include our expectations regarding financial results for the third quarter and full year 2010 and applications for the Company's OBR product. Management cautions the reader that these forward-looking statements are only predictions and are subject to a number of both known and unknown risks and uncertainties, and actual results, performance, and/or achievements of the Company may differ materially from the future results, performance, and/or achievements expressed or implied by these forward-looking statements as a result of a number of factors. These factors include, without limitation the fact that the outlook for the third quarter of and full year 2010 could change, and also include, without limitations, those risks and uncertainties set forth in the Company's periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC's website at www.sec.gov, and at the company's website at www.lunainnovations.com. The statements made in this release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements after the date of this release.
Visit this link to view the Consolidated Statements of Operations
About Luna Innovations
Luna Innovations Incorporated is focused on sensing and instrumentation, and pharmaceutical nanomedicines. Luna develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. The company's products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.
For more information, please click here
Luna Innovations Incorporated
Scott Graeff, Interim CFO
Copyright © Luna InnovationsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
IU chemists craft molecule that self-assembles into flower-shaped crystalline patterns:'Tricarb' research laid foundation for university's new $1.2 million materials science grant from National Science Foundation December 1st, 2015
Haydale Announce Year End Results November 3rd, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015